Aridis Pharmaceuticals, LLC
Aridis Pharmaceuticals is a biopharmaceutical company developing drugs to treat infectious disease.  The Company has optimized a number of product candidates by leveraging its proprietary formulation and delivery technologies.  These products have significant market potential and address unmet medical needs in the growing population of patients with serious lung diseases like pneumonia, cystic fibrosis, bronchiectasis and COPD.  With a management team responsible for several of the top drugs at Genentech and MedImmune, Aridis has advanced its pipeline through significant preclinical milestones using non-dilutive funding totaling over $8 million.

BioMarker Pharmaceuticals, Inc.
BioMarker is translating the discovery of genes that control aging into innovative therapeutics and diagnostics that can treat or prevent chronic diseases associated with aging. Therapeutic interventions based on these genes will result in a longer and healthier human lifespan. When experimental animals are fed diets that are severely restricted in total calories they exhibit a potent protection against age-related diseases like cancer, heart disease, metabolic disorders like diabetes, and neurodegenerative diseases like Alzheimer’s and Parkinson’s disease. In addition, their maximum lifespan is extended by about 30%. This approach, called calorie restriction (CR), is far too difficult to be readily adopted by people. BioMarker is identifying “CR mimetics”, which will have the same properties as CR itself. BioMarker has developed a proprietary screening approach to identify CR mimetics. We intend to deliver safe and efficacious therapeutics and wellness products to enable people to live much longer, productive and healthier lives.

BioStrategies

Chronix Biomedical, Inc.
Chronix is a genomics company that designs simple blood tests targeted at the earliest detection of chronic illnesses. Chronix�s first product, an ante mortem blood test for Bovine Spongiform Encephalopathy (�BSE� or �mad cow disease�), is currently in validation studies by the German and Canadian governments. Chronix also intends to pursue molecular diagnostic applications for variant Creutzfeldt-Jakob Disease (�vCJD�) and several cancers, including breast, lung, ovarian, and prostate. The Company has offices in San Jose, California and laboratories in Brookings, South Dakota and G�ttingen, Germany.

Collagen Solutions, LLC.
Collagen Solutions, LLC produces medical grade collagen from corium to highly processed ultra-pure soluble collagen depending on your needs. They provide development services for customized devices, technology transfer to tronact manufacturing, as well as consulting services.

Colby
Colby has developed new signal transduction, oxidative-stress and hypoxia inhibitor drugs for treatment of prostate and other solid tumors which restore normoxia and therapy-sensitivity.

Elixir Institute of Regenerative Medicine
The Elixir Institute of Regenerative Medicine (EIRM) was founded with a vision to create one of the first non-profit, non-academic, exclusively stem cell focused research institutes in the US to accelerate progress in this nascent field.

Epitex BioSystems
Epitex BioSystems is developing an improved method for genetic engineering of mammalian cells. Our proprietary technology will reduce the time required to make high yield recombinant cell lines from months to days. The continuous expression and scalability of a stable cell line make this method the fastest way to produce recombinant protein candidates for biotech research programs. Our technology can also be applied to cell based screening and therapeutic protein (and antibody) manufacturing. We are a concept stage company with patent pending engaged in demonstrating proof of principle.

GeneWeave Biosciences
- is life-science startup developing a bacterial detection platform that will revolutionize molecular diagnostics.

Genista Biosciences
Genista Biosciences is an emerging biotechnology company focused on developing a broad range of research and diagnostic tools. Genista Biosciences currently offers customized gene expression products and services for faster, cost effective biomarker discovery and validation using real time PCR (Polymerase Chain Reaction) technology. We also provide NAT (Nucleic Acid Testing) assays for Oncology research by identifying biomarkers that have prognostic and diagnostic utility. Genista Biosciences is committed to its mission to offer excellent quality and value to its clients.

HB Company
HB Company is focused on researching and developing products to benefit human health.

MedLex
MedLex develops, markets, and sells the most advanced enterprise-wide and integrated decision support and portfolio management software and systems. Our technology represents a breakthrough in decision support and management software for the pharmaceutical, biotech, and healthcare industries. Our objective is to set the industry standard for IT-based decision support technologies.

MIBA Medical Inc.
MIBA Medical, Inc. is medical aesthetics company who believe that everyone should have a choice to enhance their beauty, erase the signs of aging and regain their youthfulness without surgery. We consists of a group of industry veterans gathered under the leadership of an accomplished plastic surgeon who has the vision of making a best in class tissue filler.

nLiten Energy
nLiten Energy manufactures high-efficiency thin-film solar modules that produce affordable clean energy by using a patent-pending folded junction technology to leverage the existing thin-film solar module infrastructure. The folded junction technology significantly improves thin-film solar module conversion efficiency for any thin-film material with low additional cost.

Obura Company
Obura Company is a preclinical stage company focusing on amyotrophic lateral sclerosis (ALS). Also known as Lou Gehrig's disease, ALS is a severe and debilitating disease that affects 30,000 Americans and many more people overseas. People with ALS lose their abilities to walk, to use their hands, and to eat and speak, and eventually become dependent on respirators. With average survival from diagnosis at 3 - 5 years and no truly effective treatments currently available, new therapeutic options are urgently needed. We are currently testing our lead compound, DM201, for use in ALS, and we are also investigating mechanisms of pathogenesis of this disease.

OmegaGenesis
OmegaGenesis is the market innovator in nanotechnology based angiogenesis solutions.  Our solutions promote the growth of new blood vessels where needed to improve human health.  We are the first to use nutrient enhancement through new capillary growth to heal wounds and activate dormant cells.

Oxford BioTherapeutics
Oxford BioTherapeutics (OBT) discovers and develops targeted antibody therapeutics to deliver innovative & cost-effective medicines for major unmet patient needs in the field of oncology.

Resonance
We are Resonance (L2B Environmental Systems Inc.) and for years, we have helped home owners and corporations the world over improve the quality of their air. Whether your needs are big or small, custom or stock, there's a Resonance system the right size and price for you. And because we are world leaders in innovative air quality systems, you get the benefit of our research & development, product design and manufacturing. Resonance is your one step solution to your indoor air quality concerns. Depending upon your specific needs, we offer UVC germicidal disinfection, high reflectance UVC surface coating technology and air filtration.

Reviva Pharmaceuticals, Inc.
Reviva Pharmaceuticals is an emerging research based pharmaceutical company focused on developing a portfolio of internally discovered next generation safe and effective therapeutic drugs by using an integrated chemical genomics-based technology platform and proprietary chemistries. The company is currently focused on developing drugs for the central nervous system (CNS), cardiovascular (CV), infectious, metabolic and inflammatory diseases.

Single Cell Technology, Inc.
Central to contemporary pharmaceutical and diagnostic development is the unrelenting pursuit of tight binding molecules, �binders� for short. Once a molecular target is identified, the search is on to find binders that attach quickly, stay on for the desired period of time, bind to the exact site and that site alone, and elicit the desired diagnostic or biological response.
Single Cell Technology (SCT) has developed and patented a proprietary and unique platform to identify and characterize antibody-based binders. With innovative integration of cutting edge technologies, we deliver in a single run thousands of binders that are carefully ranked based on kinetic properties and site binding characteristics. In addition, we obtain valuable insight into the molecular target�s structure that was previously unavailable. Based on the outcome of the initial run, we can launch additional runs to optimize a number of select candidates in parallel. In short, the SCT versatile platform delivers the best of the current hybridoma and phage display technologies without their inherent limitations. In addition to seeking binders for pharmaceutical purposes, our platform can easily extend to other areas such as diagnostics and research where the burden of regulatory approval is much less.

SkyScan
SkyScan is a fast growing company and one of the world’s leading producers of micro-ct systems for a wide range of applications. Skyscan aims to bring to customers the newest technology, the best instrument quality and the highest level of support. Responding to the demand from the growing community of micro-CT users, we are continually active in research and development into new methods for non-destructive 3D microscopy.

Tacere Therapeutics, Inc.
Tacere specializes in the development of novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C. Combining expertise in RNA interference (RNAi), gene medicine, and novel biologicals, Tacere possesses proprietary skill in the identification and development of RNAi therapeutics. Tacere is currently performing IND-enabling studies on its lead therapeutic compound, TT-033.

TRICORNTECH Corporation
TRICORNTECH Corporation is developing innovative and revolutionary medical devices for rapid, non-invasive disease diagnoses and health status monitoring. The diagnostic products aim to serve the rapid growing point-of-care (POC) markets, which are essentially important as the increase of aging baby boomers and longer life span of global populations. Our pioneering approach based on semiconductor chip technology, nano-materials, and novel sensing architecture makes the products in a small form factor and affordable to serve current unmet POC market needs.
TEL: (408) 568-1589

Zymera
Zymera is a nanobiotechnology company pioneering the commercialization of self-illuminating red to near infrared (NIR) emitting quantum dot technologies for preclinical in vivo imaging and as an analytical platform for molecular detection.  Zymera develops and produces self-illuminating Qdot® nanocrystal products; these Bioluminescence Resonance Energy Transfer-Qdot® (BRET-Qdot®) conjugates convert biochemical energy to detectable photon energy through the activity of luciferase, a recombinant bioluminescence enzyme.  The BRET-Qdot® probes are active in serum and blood, can be multiplexed for in vivo imaging, and are designed as proximity- and activity-based biosensors.  Zymera holds intellectual property rights to the technology and maintains leading-edge research in nanocrystal chemistries and applications. Zymera is establishing collaborations with pharmaceutical and biotechnology companies for BRET-Qdot® probe development and applications.  The company offers a broad spectrum of research services ranging from reagent and technology development to project and program management.